Wikipedia -WSS

Wikipedia

author：hotspot 2025-10-02 10:38:41 - browse：97

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： What to watch for from Zogenix and Amicus clinical trials

hotspot

WSS

Biden launches a new push to limit health care costs

Iowa House, Senate pass 6

Former reverend arrested for allegedly killing 8

Search called off for baby washed away in Pennsylvania flash flood

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Dems pitch expanding Medicare power to negotiate drug prices

hotspot

Wikipedia

leisure time

The high cost of giving birth even with insurance

Senate panel puts off hardest PBM reforms for another day

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Leqembi, other new Alzheimer’s drugs require better biomarkers

In age of alternative facts, a scholarly course on calling out crap

Retired US general questions alleged Putin, Prigozhin meeting

How to save PrEP access — and even expand it

STAT Report: Patient voices and perspectives

Drug repurposing or repositioning? The language matters

The battle over 'scope creep' and who gets to be called 'doctor'

focus

Biden warns of ‘dark winter’ during final presidental debate

Charles Manson follower Leslie Van Houten released from prison after 53 years

'Investigate these claims': UFO transparency at center of House hearing

Palantir health business leans on meeting customers’ needs

It's time to get medical device identifiers over the finish line

It's time to get medical device identifiers over the finish line

hotspot

explore

hotspot

focus